FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366351451> ?p ?o ?g. }

• W4366351451 endingPage "2623" @default.
• W4366351451 startingPage "2622" @default.
• W4366351451 abstract "To the Editor, We previously reported that novel compound N-Succinyl-S-farnesyl-L-cysteine (SFC) possesses a broad range of anti-inflammatory, anti-aging and skin-protecting properties, including the inhibition of cathelicidin (LL-37), and toll-like receptor (TLR)-induced inflammation,1 both of which have been identified as key contributors to the pathogenesis of rosacea.2 Moreover, when tested clinically in a double-blind, vehicle-controlled study, SFC was well tolerated and significantly outperformed vehicle showing improvement of several clinical endpoints including wrinkle reduction, hydration, and overall appearance of skin.1 Given SFC is well tolerated, modulates LL-37 and TLR signaling, and that a chemically similar, less potent derivative, N-acetyl-S-farnesyl-L-cysteine (AFC), has previously been shown to reduce erythema and neutrophil infiltration in the TPA in vivo ear model,3 which is also implicated in the pathogenesis of rosacea,2 we sought to perform a pilot clinical study to assess its potential effectiveness in adult patients with rosacea. In the United States, rosacea has been estimated to affect at least 16 million, and worldwide incidence peaks as high as 18% in populations with “Celtic” heritage.4 Rosacea is characterized by erythema, blushing, and inflammatory lesions. While the pathogenesis of rosacea is not yet fully understood, inflammation is known to be the primary contributing factor to this disease.5 This open-label clinical study enrolled 10 rosacea patients that completed the study. There were seven female and three male participants with a mean age of 53.3 years ranging from 29 to 74 years. Utilizing a 3% SFC gel formulation (applied 2× daily), a majority of subjects had reduced average lesion counts, erythema, and 1–2 grade improvement on the IGA scale after 4 weeks. For example, six patients (60%) demonstrated a 1-grade change improvement, and three patients (30%) exhibited a 2-grade improvement with two subjects reaching treatment success (IGA score of clear or almost clear) (Table 1). Similarly, for CEA four patients (40%) showed a 1-grade reduction in erythema and three patients (30%) had a 2-grade reduction in redness, demonstrating that a total of 70% of the patients had their erythema reduced (Table 1). When measuring inflammatory lesions, 3% SFC gel after 4 weeks resulted in almost a 50% reduction in the average lesion count from baseline (Table 2). Lastly, SFC at 3% was well tolerated with no adverse effects. Isoprenylcysteine (IPC) molecules represent a novel class of compounds that have previously been shown to be effective against other inflammatory skin disorders such as acne.6 SFC is a new IPC compound with several skin-protecting properties that targets key players in the pathogenesis of rosacea. Though the clinical endpoints were exploratory and not powered to demonstrate changes from baseline, it is apparent that most patients demonstrated improvement in this small pilot study. The reduction in erythema, inflammatory lesions and improvement in IGA are encouraging results, and further study of SFC in a larger, controlled study of longer duration is warranted. Maxwell Stock, Jeffry B. Stock, and Michael Voronkov designed the research study, Maxwell Stock, Jeffry B. Stock, Corey Fitzgerald, and Eduardo Pérez analyzed the data. Karl Rouzard, Jason Healy, and Masanori Tamura, Michael Voronkov contributed essential reagents or tools and Eduardo Pérez wrote the paper. All authors read and approved the final letter prior to submission. All authors of this letter are paid employees or consultants of Signum Biosciences that funded the study. This multisite study was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in Title 21 of the U.S. Code of Federal Regulations (CFR) and the Declaration of Helsinki and its later amendments. All patients were informed about the details of the study protocol and informed consent was obtained. The data that support the findings of this study are available from the corresponding author upon reasonable request." @default.
• W4366351451 created "2023-04-21" @default.
• W4366351451 creator A5031049162 @default.
• W4366351451 creator A5031821829 @default.
• W4366351451 creator A5035131346 @default.
• W4366351451 creator A5060389051 @default.
• W4366351451 creator A5064674284 @default.
• W4366351451 creator A5074267870 @default.
• W4366351451 creator A5084149866 @default.
• W4366351451 creator A5090299931 @default.
• W4366351451 creator A5091160811 @default.
• W4366351451 date "2023-04-18" @default.
• W4366351451 modified "2023-10-14" @default.
• W4366351451 title "Pilot study demonstrates <scp><i>N</i>‐Succinyl‐<i>S</i>‐farnesyl‐L‐cysteine</scp> reduces erythema and inflammatory lesions in rosacea subjects" @default.
• W4366351451 cites W2027534061 @default.
• W4366351451 cites W2040189916 @default.
• W4366351451 cites W2111477301 @default.
• W4366351451 cites W2804228662 @default.
• W4366351451 cites W2902713005 @default.
• W4366351451 doi "https://doi.org/10.1111/jocd.15758" @default.
• W4366351451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37073424" @default.
• W4366351451 hasPublicationYear "2023" @default.
• W4366351451 type Work @default.
• W4366351451 citedByCount "0" @default.
• W4366351451 crossrefType "journal-article" @default.
• W4366351451 hasAuthorship W4366351451A5031049162 @default.
• W4366351451 hasAuthorship W4366351451A5031821829 @default.
• W4366351451 hasAuthorship W4366351451A5035131346 @default.
• W4366351451 hasAuthorship W4366351451A5060389051 @default.
• W4366351451 hasAuthorship W4366351451A5064674284 @default.
• W4366351451 hasAuthorship W4366351451A5074267870 @default.
• W4366351451 hasAuthorship W4366351451A5084149866 @default.
• W4366351451 hasAuthorship W4366351451A5090299931 @default.
• W4366351451 hasAuthorship W4366351451A5091160811 @default.
• W4366351451 hasBestOaLocation W43663514511 @default.
• W4366351451 hasConcept C16005928 @default.
• W4366351451 hasConcept C203014093 @default.
• W4366351451 hasConcept C2776914184 @default.
• W4366351451 hasConcept C2777673923 @default.
• W4366351451 hasConcept C2778081122 @default.
• W4366351451 hasConcept C2779121184 @default.
• W4366351451 hasConcept C2780942790 @default.
• W4366351451 hasConcept C71924100 @default.
• W4366351451 hasConcept C98274493 @default.
• W4366351451 hasConceptScore W4366351451C16005928 @default.
• W4366351451 hasConceptScore W4366351451C203014093 @default.
• W4366351451 hasConceptScore W4366351451C2776914184 @default.
• W4366351451 hasConceptScore W4366351451C2777673923 @default.
• W4366351451 hasConceptScore W4366351451C2778081122 @default.
• W4366351451 hasConceptScore W4366351451C2779121184 @default.
• W4366351451 hasConceptScore W4366351451C2780942790 @default.
• W4366351451 hasConceptScore W4366351451C71924100 @default.
• W4366351451 hasConceptScore W4366351451C98274493 @default.
• W4366351451 hasIssue "9" @default.
• W4366351451 hasLocation W43663514511 @default.
• W4366351451 hasLocation W43663514512 @default.
• W4366351451 hasOpenAccess W4366351451 @default.
• W4366351451 hasPrimaryLocation W43663514511 @default.
• W4366351451 hasRelatedWork W140508764 @default.
• W4366351451 hasRelatedWork W2004565454 @default.
• W4366351451 hasRelatedWork W2059237184 @default.
• W4366351451 hasRelatedWork W2124252059 @default.
• W4366351451 hasRelatedWork W2556913062 @default.
• W4366351451 hasRelatedWork W2771798643 @default.
• W4366351451 hasRelatedWork W2903489588 @default.
• W4366351451 hasRelatedWork W3156955667 @default.
• W4366351451 hasRelatedWork W4284665579 @default.
• W4366351451 hasRelatedWork W4298088771 @default.
• W4366351451 hasVolume "22" @default.
• W4366351451 isParatext "false" @default.
• W4366351451 isRetracted "false" @default.
• W4366351451 workType "article" @default.